Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Late-Onset Pompe Disease (LOPD) is a rare inherited metabolic disorder caused by deficient acid alpha-glucosidase, leading to progressive glycogen accumulation and muscle weakness. According to Weijing Kong et al. (2024), global birth prevalence of LOPD was 2.4 cases per 100,000 live births. As per the late-onset Pompe disease epidemiology forecast by Expert Market Research, continued epidemiological assessment supports disease understanding.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Late-Onset Pompe Disease (LOPD) – Number of Cases by Year

Read more about this report - Request a Free Sample

Late-Onset Pompe Disease (LOPD) Epidemiology Forecast Report Coverage

Expert Market Research's “Late-Onset Pompe Disease (LOPD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of late-onset Pompe disease (LOPD). It projects the future incidence and prevalence rates of late-onset Pompe disease (LOPD) cases across various populations. The study covers age, gender, and type as major determinants of the late-onset Pompe disease (LOPD) population. The report highlights patterns in the prevalence of late-onset Pompe disease (LOPD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of late-onset Pompe disease (LOPD) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Late-Onset Pompe Disease (LOPD) Understanding: Disease Overview

Late-onset Pompe disease (LOPD) is a rare inherited metabolic syndrome caused by pathogenic variants in the GAA gene, resulting in deficient acid alpha-glucosidase activity and progressive accumulation of glycogen within skeletal and respiratory muscles. It is an autosomal recessive disorder and represents one of the clinical forms of Pompe disease. Unlike infantile-onset disease, LOPD generally develops during childhood, adolescence, or adulthood and progresses more slowly. Common manifestations include progressive proximal muscle weakness, impaired mobility, and respiratory muscle involvement. Glycogen storage in muscle cells contributes to progressive tissue damage and functional decline.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

United States

High-Risk Population

Individuals with pathogenic GAA variants, particularly those with progressive skeletal or respiratory muscle weakness

Key Diagnostic Method

Enzyme activity testing supported by GAA genetic testing

Major Risk Factor

Deficiency of acid alpha-glucosidase leading to progressive glycogen accumulation

Major gap in the market

Delayed diagnosis and underdiagnosis

Late-Onset Pompe Disease (LOPD) Epidemiology Perspective

The late-onset Pompe disease (LOPD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the late-onset Pompe disease (LOPD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for late-onset Pompe disease (LOPD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Global birth prevalence of late-onset Pompe disease was 2.4 cases per 100,000 live births, according to Weijing Kong et al., https://pubmed.ncbi.nlm.nih.gov/39424261/2024.

Gender-Specific Cases of the Disease

In an Italian pediatric cohort, males accounted for 63% (24/38) of late-onset Pompe disease patients, compared with 37% (14/38) females. As reported by Marco Spada et al., 2025, this distribution provides a gender-specific profile of diagnosed pediatric cases.

Age-Specific Cases of the Disease

The Italian pediatric cohort included patients diagnosed across childhood, with 26% (10/38) diagnosed at 0–3 years and 74% (28/38) at 3–18 years, according to Marco Spada et al., 2025, demonstrating diagnosis across different pediatric age groups.

Ethnicity-Wise Cases of the Disease

Epidemiological estimates vary across ethnic populations. According to Yutaka Furuta et al., 2025, Pompe disease was reported at approximately 1 in 14,000 among African Americans compared with 1 in 100,000 among individuals of European descent, indicating substantial population-level variation.

Mortality and Survival Analysis of the Disease

Late-onset Pompe disease is associated with a progressive epidemiological burden extending from childhood into adulthood. According to Yutaka Furuta et al., 2025, adult presentation may involve progressive respiratory and neuromuscular impairment, highlighting the importance of disease recognition across the lifespan.

Late-Onset Pompe Disease (LOPD) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Late-Onset Pompe Disease (LOPD) Epidemiology

The late-onset Pompe disease (LOPD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

The United States demonstrates variation in Pompe disease epidemiology across populations. According to Yutaka Furuta et al., 2025, incidence was approximately 1 in 40,000, with reported rates of 1 in 14,000 among African Americans and 1 in 100,000 among individuals of European descent, highlighting geographic and population-level variation.

Germany

Germany contributes to the broader European epidemiological landscape of Pompe disease, where estimates can vary according to population characteristics and diagnostic approaches. As per Roberto Giugliani et al., 2025, differences in screening and diagnostic methodologies contribute to variation in reported epidemiological estimates across geographic regions.

France

France has demonstrated an increasing pattern of late-onset Pompe disease diagnosis over time. According to Roberto Giugliani et al., 2025, the French National Pompe Registry recorded diagnoses increasing.

Italy

Italy has documented a defined pediatric late-onset Pompe disease population. According to Marco Spada et al., 2025, 38 pediatric patients were identified, including 63% males and 37% females; 26% were diagnosed at 0–3 years and 74% at 3–18 years.

Spain

Spain forms part of the European epidemiological context in which Pompe disease estimates vary according to geographic population characteristics and diagnostic approaches. Based on the provided evidence, the epidemiological profile is characterized by the broader European pattern of variation in disease identification and diagnosis.

United Kingdom

The United Kingdom forms part of the European Pompe disease epidemiological landscape. According to Roberto Giugliani et al., 2025, epidemiological estimates across regions are influenced by differences in diagnostic methods, screening approaches, and disease classification, factors relevant to interpretation of regional disease burden.

Japan

Japan demonstrates distinct epidemiological patterns within Asian populations. According to Roberto Giugliani et al., 2025, newborn-screening studies reported infantile-onset Pompe disease birth prevalence of 1 in 297,387, while Asian populations have also demonstrated a higher frequency of pseudodeficiency alleles.

India

India represents an Asian population within the broader geographic variation observed for Pompe disease epidemiology. As per Roberto Giugliani et al., 2025, epidemiological estimates can vary across geographic and ethnic populations, while differences in screening and diagnostic practices influence identification of affected individuals.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional disease epidemiology landscape for Late-Onset Pompe Disease is characterized by persistent underdiagnosis and delayed diagnosis, largely because its symptoms can overlap with other neuromuscular disorders. Limited disease awareness among healthcare professionals and the rarity of the condition can further delay referral for confirmatory testing. An important opportunity exists to strengthen diagnostic pathways through greater use of enzyme activity testing and molecular confirmation, particularly in patients presenting with unexplained progressive muscle weakness or respiratory dysfunction. Expanding specialist networks and improving access to enzyme replacement therapy may also support earlier intervention across the United States, European markets, Japan, and India.

Late-Onset Pompe Disease (LOPD): Treatment Overview

Late-onset Pompe disease treatment primarily focuses on reducing glycogen accumulation, preserving muscle function, and slowing disease progression. Enzyme replacement therapy (ERT) is the principal disease-specific treatment and involves intravenous administration of recombinant acid alpha-glucosidase to supplement deficient enzyme activity. Available ERT options include alglucosidase alfa and newer enzyme formulations, depending on regulatory approval and clinical availability. Supportive management is also important and may include respiratory support, physical therapy, exercise programs, nutritional management, and mobility assistance. Regular assessment of respiratory, motor, and swallowing function helps guide individualized treatment and disease monitoring.

Key Questions Answered

  • What is the current and projected burden of late-onset Pompe disease (LOPD) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest late-onset Pompe disease (LOPD) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of late-onset Pompe disease (LOPD) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of late-onset Pompe disease (LOPD) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of late-onset Pompe disease (LOPD) across the 8 major markets?
  • How do major comorbidities and risk factors influence late-onset Pompe disease (LOPD) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of late-onset Pompe disease (LOPD) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the late-onset Pompe disease (LOPD) landscape across the 8 major markets?
  • Which therapeutic areas linked to late-onset Pompe disease (LOPD) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the late-onset Pompe disease (LOPD) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major marketsoffer the most attractive market opportunities based on late-onset Pompe disease (LOPD) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for late-onset Pompe disease (LOPD) across the 8 major markets?

Scope of the Late-Onset Pompe Disease (LOPD) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of late-onset Pompe disease (LOPD) based on several factors.
  • Late-Onset Pompe Disease (LOPD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The late-onset Pompe disease (LOPD) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Rare Diseases Treatment Market

Genetic Cardiomyopathies Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us